Promising Immunotherapy Approach for Medulloblastoma Revealed in New Study

Strategic Insights -

Researchers at the Research Institute Children's Cancer Center Hamburg have made a significant breakthrough in developing an immunotherapy approach for treating medulloblastoma, a type of pediatric brain cancer. Despite the current standard of care, which involves aggressive surgery and chemotherapy, this new study demonstrates a potential for targeted therapies that can selectively target tumor cells with minimal side effects. The research team has created a single chain variable fragment (scFv)-based immunotoxin that incorporates a truncated variant of Pseudomonas Exotoxin A, which specifically targets the epidermal growth factor receptor (EGFR) commonly overexpressed in SHH-medulloblastoma.

Key Takeaways:

  • The research team generated an scFv-based immunotoxin that targets the EGFR, a tumor-associated antigen commonly overexpressed in SHH-medulloblastoma, with IC50 values ranging from 3.1 to 17.5 nM.
  • The combination of the immunotoxin with a PI3K inhibitor led to dose-dependent reductions in IC50 values, from 2.51-13.9 nM at 0.5 M start concentration to 1.01-3.4 nM at 2 M start concentration.
  • The immunotherapeutic approach successfully crossed the blood-brain barrier in vitro in an in vitro BBB-model based on human brain microvascular endothelial (HBMEC) cells.
  • The research suggests that this immunotherapeutic approach is a promising candidate for further development and clinical application.
  • SHH-medulloblastoma exhibits dysregulated PI3-kinase (PI3K) pathway signaling, which the researchers aimed to target with the PI3K inhibitor.

Statistics:

  • IC50 values ranged from 3.1 to 17.5 nM for the scFv-based immunotoxin.
  • Combination treatment with a PI3K inhibitor resulted in dose-dependent reductions in IC50 values, from 2.51-13.9 nM at 0.5 M start concentration to 1.01-3.4 nM at 2 M start concentration.
  • The immunotherapy approach successfully crossed the blood-brain barrier in vitro in an in vitro BBB-model based on human brain microvascular endothelial (HBMEC) cells.

Sources:

  • NewsRx LLC
  • Research Institute Children's Cancer Center Hamburg
  • Cancer Treatment and Research Communications
  • Elsevier
  • https://doi-org.sdpl.idm.oclc.org/10.1016/j.ctarc.2025.100950